Dermatology-Plastic Surgery | Mapi Research Trust

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2019. D’Angelo SP et al. – Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
2018. Bharmal M et al. – Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: Innovative use of patient insights
2018. Kaufman HL et al. – Living with Merkel cell carcinoma (MCC): Development of a conceptual model of MCC based on patient experiences
2018. Bharmal M et al. – How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
2018. Kaufman HL et al. – Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma
2017. Bharmal M et al. – Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
2017. Mohr PM et al. – Real world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab
2017. McArthur et al. – Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with Ipilimumab (INTUITION Study)
2017. Brengard-Bresler T et al. – Postoperative quality of life of patients with a bacterial necrotizing dermis-hypodermitis or necrotizing fasciitis, a ten-year study
2016. Svedbom A et al. – Economic burden of psoriasis and potential cost offsets with biologic treatment: A Swedish register analysis
2015. Svedbom A et al. – Increased cause-specific mortality in patients with mild and severe psoriasis: A population-based Swedish register study
2015. Gilet H et al. – Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: A common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians
2015. Svedbom A et al. – Treatment patterns with topicals, traditional systemics and biologics in psoriasis – A Swedish database analysis
2012. Dequen et al. – Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma
2011. Van de Kerkhof et al. – Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris

Posters & Presentations

2017. ESMO Immuno-Oncology Congress – Health-Related Quality of Life (HRQoL) in Patients (Pts) With Merkel Cell Carcinoma (MCC) Receiving Avelumab (81P)
2017. ISPOR European Congress – Minimal Impact on Patients’ Health Utilities Associated with Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment with Avelumab
2017. ISPOR European Congress – Development of a tool to quantify an individual’s history of sun exposure: Qualitative phase of the development of the Sun Exposure Questionnaire
2017. ISPOR European Meeting – Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from CheckMate 067
2017. ISPOR European Congress – Using convergent mixed methods to evaluate treatment risks and benefits in rare disease: An example from a Phase II registration trial in metastatic Merkel Cell Carcinoma
2017. ISPOR European Congress – Cost of nivolumab in combination with ipilimumab as first line treatment in advanced melanoma across various European markets
2017. EADV Congress – French translation of the Simplified Psoriasis Index
2017. ASCO Annual Meeting – Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel Cell Carcinoma
2017. ASCO Annual Meeting – Patient experiences with avelumab vs chemotherapy for treating Merkel Cell Carcinoma: Results from protocol-specified qualitative research
2017. ISPOR Annual International Meeting – Psychometric validation of the FACT-M questionnaire in patients with Merkel Cell Carcinoma
2017. ISPOR Annual International Meeting – Non-progression on treatment with avelumab contributed to gains in health utility scores with metastatic Merkel Cell Carcinoma
2017. AEDV – Congreso Nacional de Dermatologia y Venereologia – Cost-effectiveness of ixekizumab vs. secukinumab in the treatment of moderate to severe plaque psoriasis in Spain
2016. ISPOR European Congress – Budget impact of apremilast for moderate to severe plaque psoriasis in the UK
2016. ISPOR European Congress – Cost-effectiveness of apremilast in moderate to severe psoriasis in Canada
2016. ISPOR European Congress – Cost-effectiveness analysis of ixekizumab vs. secukinumab in sequential biologic treatment of psoriasis in the UK
2015. ISPOR Annual European Congress – Cost-Effectiveness of Apremilast in Moderate to Severe Psoriasis in Scotland
2015. ISPOR Annual European Congress – Does Health-Related Quality of Life Evaluation in Psoriasis Matter? A Review of Labels of Psoriasis Products Approved by the FDA and the EMA
2014. ISPOR Annual European Congress – Assessing the Relationship Between Treatment Effect and Baseline Risk in Network Meta-Analysis of Moderate to Severe Chronic Plaque Psoriasis Trials
2014. ISPOR Annual International Meeting – Comparability of Trial Populations in Network Meta-Analyses Assessing Biologic Treatments in Moderate to Severe Plaque Psoriasis
2013. European Academy of Dermatology and Venereology (EADV) Congress – Finalisation and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire
2012. ISPOR European Congress – Efficacy of Ceftaroline Fosamil and Other Intravenous Antibiotics in the Treatment of Complicated Skin and Soft Tissue Infections (CSSTI): A Network Meta-Analysis (NMA)
2012. ISPOR Annual International Meeting – Psychometric Validation of the Tummy Tuck Questionnaire
2012. Infectious Disease Research Network. Primary Care Database Symposium – The use of GP questionnaires to assess psoriasis severity in The Health Improvement Network (THIN) database
2011. ISOQOL Annual Conference – Content Assessment of the Facial Line Outcomes (FLO-11) Questionnaire
2011. European Academy of Dermatology and Venereology (EADV) Congress – Development of a unique tool reflecting patient and physician perceptions of psoriasis severity and treatment efficacy
2011. ISPOR Annual International Meeting – Gap Analysis for Patient-Reported Outcomes Measures for Alopecia
2010. ISPOR European Congress – Development of an Instrument Mirroring Patient and Physician Perception of Psoriasis Severity and Treatment Effect
2010. ISPOR Annual International Meeting – Comparison of the PRO Endpoints found in Labeling Claims of Products for the Treatment of Psoriasis with Those Recommended by the Corresponding EMA Guidance
2008. ISPOR European Congress – A Disease Model Illustrating the Impact of Psoriasis on Patients’ Lives